The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Autor: Hadji, Peyman, Stoetzer, Oliver, Decker, Thomas, Kurbacher, Christian M., Marmé, Frederik, Schneeweiss, Andreas, Mundhenke, Christoph, Distelrath, Andrea, Fasching, Peter A., Lux, Michael P., Lüftner, Diana, Janni, Wolfgang, Muth, Mathias, Kreuzeder, Julia, Quiering, Claudia, Grischke, Eva-Marie, Tesch, Hans
Zdroj: In Journal of Bone Oncology February 2019 14
Databáze: ScienceDirect